Mariana Zorrón Mei Hsia Pu

Mariana Zorrón Mei Hsia Pu

Auto-generated profile, based on publicly available information

Mariana Zorrón Mei Hsia Pu

Universidade Estadual de Campinas Faculdade de Ciências Médicas e Hospital de Clínicas Departamento de Pediatria CampinasSP Brasil Departamento de Pediatria, Faculdade de Ciências Médicas e Hospital de Clínicas, Universidade Estadual de Campinas, Campinas, SP, Brasil

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2022 in Jornal Brasileiro de Pneumologia
Verified
Journal Article
Open access
MZMariana Zorron1
Mariana Zorron1
FMFernando Augusto Lima Marson
Fernando Augusto Lima Marson
AMAndré Moreno Morcillo
André Moreno Morcillo
AGAline Cristina Gonçalves
Aline Cristina Gonçalves
MBMayra de Souza El Beck1
Mayra de Souza El Beck1
ARAntonio Fernando Ribeiro1
Antonio Fernando Ribeiro1
Objective: To determine whether abnormal continuous glucose monitoring (CGM) readings (hypoglycemia/hyperglycemia) can predict the onset of cystic fibrosis-related diabetes (CFRD) and/or clinical impairment (decline in BMI and/or FEV1) in pediatric patients with cystic fibrosis (CF). Methods: This was a longitudinal prospective cohort study involving CF patients without diabetes at baseline. The mean follow-up period was 3.1 years. The patients underwent 3-day CGM, performed oral glucose tolerance test (OGTT), and had FEV1 and BMI determined at baseline. OGTT, FEV1, and BMI were reassessed at the end of the follow-up period. Results: Thirty-nine CF patients (10-19 years of age) had valid CGM readings at baseline, and 34 completed the follow-up period (mean = 3.1 ± 0.5 years). None of the study variables predicted progression to CFRD or were associated with hypoglycemic events. CGM could detect glucose abnormalities not revealed by OGTT. Patients with glucose levels = 140 mg/dL, as compared with those with lower levels, on CGM showed lower BMI values and z-scores at baseline-17.30 ± 3.91 kg/m2 vs. 19.42 ± 2.07 kg/m2; p = 0.043; and -1.55 ± 1.68 vs. -0.17 ± 0.88; p = 0.02, respectively-and at the end of follow-up-17.88 ± 3.63 kg/m2 vs. 19.95 ± 2.56 kg/m2; p = 0.039; and -1.65 ± 1.55 vs. -0.42 ± 1.08; p = 0.039. When comparing patients with and without CFRD, the former were found to have worse FEV1 (in % of predicted)-22.67 ± 5.03 vs. 59.58 ± 28.92; p = 0.041-and a greater decline in FEV1 (-36.00 ± 23.52 vs. -8.13 ± 17.18; p = 0.041) at the end of follow-up. Conclusions: CGM was able to identify glucose abnormalities not detected by OGTT that were related to early-stage decreases in BMI. CGM was ineffective in predicting the onset of diabetes in this CF population. Different diagnostic criteria for diabetes may be required for individuals with CF.

29 January 2018 in Archives of Disease in Childhood
Verified
Journal Article
Closed access
PDF file
MPMariana Zorrón Mei Hsia Pu
Mariana Zorrón Mei Hsia Pu
AGAline Cristina Gonçalves
Aline Cristina Gonçalves
WMWalter José Minnicucci
Walter José Minnicucci
AMAndré Moreno Morcillo
André Moreno Morcillo
JRJosé Dirceu Ribeiro
José Dirceu Ribeiro
ARAntonio Fernando Ribeiro
Antonio Fernando Ribeiro
Objective: This study aimed to determine the glycaemic profile of patients with cystic fibrosis using a continuous glucose monitoring system (CGMS), and to evaluate the associations of glycaemic abnormalities with sex, age, pubertal stage,CFTRgene mutations, nutritional status, lung function, oral glucose tolerance test, glycated haemoglobin concentrations, fasting insulin concentrations, C peptide concentrations and exocrine pancreatic function.Study design: This observational study evaluated CGMS data from 39 patients with cystic fibrosis who were treated at a referral centre. The patients were 10–19.9 years old, and were categorised according to whether they had normal results (27 patients) or glucose intolerance (12 patients) during the oral glucose tolerance test.Results: The maximum interstitial glucose concentration among individuals with normal oral glucose tolerance test results was 174.9±65.1 mg/dL (9.7–3.61 mmol/L), compared with 170.4±40.9 mg/dL (9.46–2.27 mmol/L) among individuals with glucose intolerance. The CGMS revealed that 18 of the 27 patients with normal oral glucose tolerance test results had peak interstitial glucose concentrations of >140 mg/dL (7.8 mmol/L), and that 4 of these individuals had peak levels of >200 mg/dL (11.1 mmol/L). None of the analysed clinical or laboratory characteristics predicted the occurrence of hyperglycaemic peaks on CGMS.Conclusions: The present study revealed that CGMS could detect hyperglycaemia among patients with cystic fibrosis and ‘normal’ oral glucose tolerance test results, and that their clinical and laboratory characteristics were not useful in discerning between patients who did and did not exhibit these excursions.

1 September 2016 in Revista Paulista de Pediatria (English Edition)
Verified
Journal Article
Open access
MPMariana Zorrón Mei Hsia Pu
Mariana Zorrón Mei Hsia Pu
FCFlávia Corrêa Christensen-Adad
Flávia Corrêa Christensen-Adad
AGAline Cristina Gonçalves
Aline Cristina Gonçalves
WMWalter José Minicucci
Walter José Minicucci
JRJosé Dirceu Ribeiro
José Dirceu Ribeiro
ARAntonio Fernando Ribeiro
Antonio Fernando Ribeiro
To elucidate whether insulin is effective or not in patients with cystic fibrosis before the diabetes mellitus phase. The study was performed according to the Prisma method between August and September 2014, using the PubMed, Embase, Lilacs and SciELO databases. Prospective studies published in English, Portuguese and Spanish from 2002 to 2015, evaluating the effect of insulin on weight parameters, body mass index and pulmonary function in patients with cystic fibrosis, with a mean age of 17.37 years before the diabetes mellitus phase were included. Eight articles were identified that included 180 patients undergoing insulin use. Sample size ranged from 4 to 54 patients, with a mean age ranging from 12.4 to 28 years. The type of follow-up, time of insulin use, the dose and implementation schedule were very heterogeneous between studies. There are theoretical reasons to believe that insulin has a beneficial effect in the studied population. The different methods and populations assessed in the studies do not allow us to state whether early insulin therapy should or should not be carried out in patients with cystic fibrosis prior to the diagnosis of diabetes. Therefore, studies with larger samples and insulin use standardization are required. Elucidar se a insulina é eficaz ou não em pacientes com fibrose cística antes da fase de diabetes. O estudo foi feito de acordo com o método Prisma entre agosto e setembro de 2014, nas bases de dados PubMed, Embase, Lilacs e SciELO. Foram incluídos estudos prospectivos publicados em inglês, português e espanhol de 2002 a 2015 que avaliaram o efeito da insulina nos parâmetros peso, índice de massa corporal e função pulmonar, em pacientes com fibrose cística, com média de 17,37 anos, antes da fase de diabetes. Foram identificados oito artigos que incluíram 180 indivíduos submetidos ao uso de insulina. O tamanho das amostras variou de 4 a 54 pacientes, idade média entre 12,4 e 28 anos. O tipo de acompanhamento, o tempo de uso de insulina, a dose e o cronograma de implementação foram muito heterogêneos entre os estudos. Existem razões teóricas para se acreditar que a insulina tenha um efeito benéfico na população estudada. Os diferentes métodos e populações encontrados não permitem afirmar se a terapia precoce com insulina deve ou não ser feita em pacientes com fibrose cística previamente ao diagnóstico de diabetes. Portanto, são necessários estudos com amostras maiores e uniformidade de uso da insulina.

24 September 2024 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
CLCarolina Paniago Lopes
Carolina Paniago Lopes
GGGentil Ferreira Gonçalves
Gentil Ferreira Gonçalves
MPMaria Fernanda Vanti Macedo Paulino
Maria Fernanda Vanti Macedo Paulino
AEAdriana Mangue Esquiaveto-Aun
Adriana Mangue Esquiaveto-Aun
MMMaricilda Palandi De Mello
Maricilda Palandi De Mello
Gil Guerra-JuniorGil Guerra-Junior
Gil Guerra-Junior
Objective: Considering the rarity and clinical and molecular diversity of Wolfram syndrome (WS), the objective of this study was to identify patients with a clinical presentation suggestive of WS following up at a single Brazilian diabetes service and analyze their clinical and molecular characteristics. Subjects and methods: The study included all patients with a clinical presentation of WS following up between 1991 and 2022 with early-onset diabetes mellitus and other WS signs and symptoms. A retrospective analysis was conducted, [...] ABSTRACT Objective: Considering the rarity and clinical and molecular diversity of Wolfram syndrome (WS), the objective of this study was to identify patients with a clinical presentation suggestive of WS following up at a single Brazilian diabetes service and analyze their clinical and molecular characteristics. Subjects and methods: The study included all patients with a clinical presentation of WS following up between 1991 and 2022 with early-onset diabetes mellitus and other WS signs and symptoms. A retrospective analysis was conducted,

26 June 2021
Verified
Preprint
Open access
PDF file
MZMariana Zorron
Mariana Zorron
FMFernando Marson
Fernando Marson
AMAndré Morcillo
André Morcillo
AGAline Gonçalves
Aline Gonçalves
MBMayra de Souza El Beck
Mayra de Souza El Beck
ARAntônio Ribeiro
Antônio Ribeiro
Background and Objectives: Cystic fibrosis-related diabetes is the major comorbidity in cystic fibrosis and reduces life expectancy, highlighting the need for early diagnosis and treatment. This study aimed to verify whether abnormal continuous glucose monitoring results predict cystic fibrosis-related diabetes onset and/or a decline in the forced expiratory volume in the 1st second or body mass index of patients with cystic fibrosis. Methods: Thirty-nine patients with cystic fibrosis (age 10–19 years) were screened for cystic fibrosis-related diabetes using the oral glucose tolerance test. Patients without diabetes diagnose underwent 3 days of continuous glucose monitoring, spirometry and body mass index measurements and were reassessed at the end of the study with a second spirometry, body mass index evaluation and oral glucose tolerance test. Results: Thirty-four patients completed the follow-up (3.1±0.51 years). None of the study variables predicted cystic fibrosis-related diabetes progression or were associated with hypoglycemic events. Continuous glucose monitoring could detect glucose abnormalities not revealed in the oral glucose tolerance test. Patients with glucose level of >140 mg/dL on continuous glucose monitoring showed significantly lower body mass index z scores at both study initiation (-1.55±1.68 vs. -0.17±0.88; p-value=0.02) and completion (-1.65±1.55 vs. -0.42±1.08; p-value=0.039). Conclusions: Continuous glucose monitoring can identify glucose abnormalities not detected by oral glucose tolerance test that are related to early stage decreases in body mass index. However, it was ineffective in predicting the onset of diabetes in this cystic fibrosis population. Different diagnostic criteria for diabetes may be required for individuals with cystic fibrosis.

22 June 2026 in Journal of Human Growth and Development
Verified
Journal Article
Open access
RGRenata Guirau
Renata Guirau
LALuana Arpini
Luana Arpini
JMJuliana Ferreira Mauri
Juliana Ferreira Mauri
MNMarcelo Coelho Nogueira
Marcelo Coelho Nogueira
VAValéria Laguna Salomão Ambrósio
Valéria Laguna Salomão Ambrósio
LNLenycia de Cassya Lopes Neri
Lenycia de Cassya Lopes Neri
Introduction: cystic fibrosis is a multisystem genetic disorder whose clinical course is strongly associated with nutritional status. Advances in diagnosis and treatment, particularly the introduction of CFTR modulators, have substantially changed the nutritional profile of affected individuals, making an update of national nutritional care recommendations necessary. Objective: to update the Brazilian Guidelines for Nutrition in Cystic Fibrosis by establishing a national, evidence-based consensus to guide nutritional assessment, monitoring, and interventions throughout the life course. Methods: these guidelines were developed by a multidisciplinary committee of Brazilian experts based on a review of national and international literature published up to September 2025, followed by a structured consensus process using the Delphi technique. The recommendations addressed nutritional assessment, macronutrient and micronutrient intake, supplementation, oral, enteral, and parenteral nutritional support, pancreatic enzyme replacement therapy, and the nutritional management of comorbidities and special clinical situations. Results: standardized parameters for anthropometric and body composition assessment were established, with emphasis on fat-free mass as a relevant prognostic marker. Updated recommendations for energy and nutrient requirements across different age groups are presented, including specific guidance for individuals receiving CFTR modulators. Clinical criteria for nutritional supplementation and specialized nutritional support were defined, along with monitoring protocols and practical guidance for the nutritional management of comorbidities associated with cystic fibrosis. All recommendations achieved a high level of agreement among the participating experts. Conclusion: this update consolidates a multidisciplinary, evidence-based national consensus, aligned with international guidelines and adapted to the Brazilian context, providing support for clinical decision-making and contributing to the improvement of nutritional care for individuals with cystic fibrosis.